- Home
- NBR vs ORIC Comparison
NBR vs ORIC Comparison
Compare NBR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- ORIC
- Stock Information
- Founded
- NBR 1952
- ORIC 2014
- Country
- NBR Bermuda
- ORIC United States
- Employees
- NBR N/A
- ORIC N/A
- Industry
- NBR Oil & Gas Production
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- ORIC Health Care
- Exchange
- NBR Nasdaq
- ORIC Nasdaq
- Market Cap
- NBR 417.7M
- ORIC 362.9M
- IPO Year
- NBR N/A
- ORIC 2020
- Fundamental
- Price
- NBR $30.31
- ORIC $10.50
- Analyst Decision
- NBR Hold
- ORIC Strong Buy
- Analyst Count
- NBR 8
- ORIC 8
- Target Price
- NBR $44.50
- ORIC $18.83
- AVG Volume (30 Days)
- NBR 545.2K
- ORIC 1.1M
- Earning Date
- NBR 07-29-2025
- ORIC 08-11-2025
- Dividend Yield
- NBR N/A
- ORIC N/A
- EPS Growth
- NBR N/A
- ORIC N/A
- EPS
- NBR N/A
- ORIC N/A
- Revenue
- NBR $2,932,608,000.00
- ORIC N/A
- Revenue This Year
- NBR $13.65
- ORIC N/A
- Revenue Next Year
- NBR $5.53
- ORIC N/A
- P/E Ratio
- NBR N/A
- ORIC N/A
- Revenue Growth
- NBR N/A
- ORIC N/A
- 52 Week Low
- NBR $23.27
- ORIC $3.90
- 52 Week High
- NBR $105.96
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- NBR 53.01
- ORIC 71.20
- Support Level
- NBR $27.33
- ORIC $9.80
- Resistance Level
- NBR $31.73
- ORIC $11.19
- Average True Range (ATR)
- NBR 2.10
- ORIC 0.61
- MACD
- NBR -0.17
- ORIC -0.04
- Stochastic Oscillator
- NBR 38.57
- ORIC 83.33
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.